TNF inhibitor safety
Executive Summary
Safety of tumor necrosis factor inhibitors and a possible link to lymphoma will be discussed by FDA's Arthritis Drugs Advisory Committee March 4. The committee will receive safety updates on all three marketed TNF inhibitors - Amgen's Enbrel, Centocor's Remicade and Abbott's Humira. The committee's TNF inhibitor safety review in August 2001 focused on the risk of immune disorders (1"The Pink Sheet" Aug. 20, 2001, p. 7)...
You may also be interested in...
Amgen Enbrel Focus Includes Push For Earlier Treatment Of RA Patients
Amgen's marketing strategy for Enbrel (etanercept) includes closing the gap between diagnosis and initiation of therapy in patients with moderate rheumatoid arthritis
Centocor Remicade Black Box MD Visits Will Be 85% Complete By Aug. 31
Centocor sales representatives will visit 85% of targeted Remicade prescribers by the end of August to inform them of a new black box warning added to labeling for the rheumatoid arthritis therapy, Exec Director-Medical Affairs Tom Schaible, PhD, told the FDA Arthritis Advisory Committee.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”